Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection

AbstractImmune thrombocytopenic purpura (ITP) is a life-threatening complication following pegylated interferon alpha (PEG-IFN) plus ribavirin treatment, the standard treatment for hepatitis C virus (HCV) infection. We reported a rare case with late-onset ITP after withdrawal of PEG-IFN treatment.A 53-year-old male with hepatitis C developed massive gum bleeding and a severe, reversible, immune thrombocytopenia 2 weeks after cessation of PEG-IFN treatment for HCV due to anemia and depression. The platelet count decreased to 4000 cells/&mgr;L. The HCV viral load was undetectable at the end of PEG-IFN treatment and during follow-up for 5 months. Other potential autoimmune disorders were ruled out. Late-onset ITP associated with PEG-IFN treatment was diagnosed.The patient was treated successfully with steroid and azathioprine. Platelet count gradually increased to 117 × 103 cells/&mgr;L on the 18th day after admission.ITP is a rare complication in patients with hepatitis C or in patients who received PEG-IFN treatment. The particular case supported that it may occur even after withdrawal of PEG-IFN treatment. Physicians should be aware of this late-onset complication.

[1]  C. Belizna.  Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. , 2015, Autoimmunity reviews.

[2]  I. Papakonstantinou,et al.  Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection. , 2014, Hippokratia.

[3]  J. Pawlotsky.  New hepatitis C therapies: the toolbox, strategies, and challenges. , 2014, Gastroenterology.

[4]  M. Weisman,et al.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE , 2012, Nature Reviews Rheumatology.

[5]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[6]  G. Espinosa,et al.  Antiphospholipid syndrome: frequency, main causes and risk factors of mortality , 2010, Nature Reviews Rheumatology.

[7]  O. Markovic,et al.  [Late onset of severe thrombocytopenia during interferon treatment for chronic hepatitis C infection--case report]. , 2010, Srpski arhiv za celokupno lekarstvo.

[8]  Hyun Soo Hong,et al.  Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C. , 2010, Internal medicine.

[9]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[10]  N. Fotos,et al.  Late onset autoimmune thrombocytopenia associated with pegylated interferon‐α‐2b plus ribavirin treatment for chronic hepatitis C , 2006, Journal of gastroenterology and hepatology.

[11]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  T. Demirdal,et al.  Autoimmune thrombocytopenia induced by PEG-IFN-α plus ribavirin in hepatitis C , 2006, Platelets.

[13]  O. Lambotte,et al.  Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. , 2005, The Journal of infection.

[14]  I. Weitz.  Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti‐CD20 monoclonal antibody, rituximab , 2005, American journal of hematology.

[15]  S. Seki,et al.  Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. , 2003, Hepato-gastroenterology.

[16]  M. Deutsch,et al.  Pegylated Interferon-2b-Associated Autoimmune Thrombocytopenia in a Patient With Chronic Hepatitis C , 2003, American Journal of Gastroenterology.

[17]  M. Fried,et al.  Side effects of therapy of hepatitis C and their management , 2002, Hepatology.

[18]  S. Kamal,et al.  Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. , 2002, Gastroenterology.

[19]  I. Khouri,et al.  Immune Thrombocytopenic Purpura , 2018 .

[20]  D. Häussinger,et al.  Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. , 2002, Digestive diseases and sciences.

[21]  S. Sauleda,et al.  Anticardiolipin Antibodies in Patients with Chronic Hepatitis C Virus Infection: Characterization in Relation to Antiphospholipid Syndrome , 2000, Clinical Diagnostic Laboratory Immunology.

[22]  M. Margaglione,et al.  Anticardiolipin antibodies in patients with liver disease , 1999, American Journal of Gastroenterology.

[23]  T. Sauerbruch,et al.  Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  F. Muñoz-Rodríguez,et al.  Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. , 1999, Journal of hepatology.

[25]  V. Leroy,et al.  Prevalence and significance of anticardiolipin, anti‐β2 glycoprotein I and anti‐prothrombin antibodies in chronic hepatitis C , 1998 .

[26]  S. Hadziyannis,et al.  Immune thrombocytopenia and α-interferon therapy , 1996 .

[27]  S. Hadziyannis,et al.  Immune thrombocytopenia and alpha-interferon therapy. , 1996, Journal of hepatology.